固相萃取-气相色谱法提取全血中的外源性褪黑素

目的建立血样中褪黑素的固相萃取方法。方法采用OasisHLB固相萃取柱提取,GC/NPD定量检验,GC/MS定性检验。结果血样中褪黑素平均萃取回收率达80%以上,最低检出限0.02μg/mL,线性良好,相关系数R2=0.9978。结论该方法操作简便快速,提取回收率高,重现性好,提取物干净,可用于实际案件当中。     

SPE-GC／MS检测生物样品中利多卡因、罗哌卡因、布比卡因

目的建立生物样品中利多卡因、罗哌卡因、布比卡因的固相萃取提取方法和气质检测方法。方法采用Oasis HLB固相萃取柱,以GC／MS定性定量。结果生物样品中利多卡因、罗哌卡因、布比卡因平均萃取回收率达74％以上,检测限0．01μg／mL,线性关系良好,相关系数R2=0．9900以上。结论方法操作简便快速,萃取回收率高,重现性好,可用于实际案件。     

全血中扎来普隆两种萃取方法的比较

目的建立血样中扎来普隆的液液萃取和固相萃取方法。方法液液萃取方法是在碱性条件下用二氯甲烷提取。固相萃取是采用OasisHLB固相萃取柱提取,萃取液均用GC/NPD检验,并对其进行比较。结果血样中扎来普隆固相萃取平均回收率达89%以上,液液萃取平均回收率为84%,GC/NPD最低检出限为2×10-2μg.mL-1。结论两种方法均能满足实际检案的需求,而固相萃取方法在减少仪器损耗和内源性杂质干扰方面具有较大的优势。     

HPLC-MS／MS同时检测全血中佐匹克隆、唑吡坦和扎来普隆

目的建立全血中佐匹克隆、唑吡坦和扎来普隆的液相色谱一四级杆飞行时间串联质谱联用同时检测方法。方法采用液液萃取进行提取,提取物以ZorbaxEclipsePlusC18（2．1×50mm,1．8fire）色谱柱分离,以10mmol／L甲酸铵（含0．1％甲酸）一乙腈为流动相梯度洗脱,流速为0．2mL／min,四级杆一飞行时间串联质谱检测。结果全血中佐匹克隆和扎来普隆的线性范围为10ng／mL-500ng／mL,检出限为3ng／mL唑吡坦的线性范围为3ng／mL-300ng／mL,检出限为lng／mL。结论本方法准确、快速、灵敏,可用于全血中佐匹克隆、唑吡坦和扎来普隆的同时定性、定量检测。     

固相萃取GC／MS分析血中10种常见农药和杀鼠药

目的 采用固相萃取（SPE）GC／MS分析技术,快速检验血中常见农药及杀鼠药。方法采用SPE-GC／MS法分析血中马拉硫磷、敌敌畏、甲基对硫磷、甲拌磷、灭多威、杀鼠迷、速灭威、久效磷、毒死蜱、灭害威等10种药物;比较OasisHLBcartridge、C18和C23种固相萃取柱同步提取的回收率及洗脱剂种类、洗脱剂和缓冲液用量对回收率的影响。结果固相萃取柱Oasis HLB cartridge提取率较高,在72．6％-112．0％之间;采用3mL氯仿做洗脱剂时回收率较好,在75．7％～127．2％之间;2mL磷酸盐为缓冲液最佳剂量。结论本文方法具有操作简便快捷,回收率高、重现性好、无杂质干扰等特点,可用于法庭毒物的检验。     

SPE—GC／MS、GC／NPD法检测血液中苯丙胺类毒品

目的利用GC／MS、GC／NPD与固相萃取（SPE）技术相结合,建立血液中苯丙胺类毒品的定性定量分析方法。方法采用Bond—ElutCerti{y固相柱、甲醇淋洗、二氯甲烷／异丙醇／氨水（78／20／2）洗脱固相萃取分离提取,比较了不同PH体系、稀释状态、洗脱溶剂对提取回收率的影响,建立血液中苯丙胺类毒品的GC／MS、GC／NPD定性定量分析方法。结果以GC／NPD分析AM、MA、MDA和MDMA浓度在15ng／mL-2000ng／mL、10ng／mL～1600ng／mL、20ng／mL-3000ng／ml、20ng／mL-3000ng／mL范围内线性关系良好,AM、MA、MDA和MDMA的检测限分别为10ng／mL、8ng／mL、15ng／mL、15ng／mL,方法平均回收率大于85％,标准偏差小于5％,GC／MS-Scan检测限分别为40ng／mL、32．0ng／mL、60．0ng／mL、60．0ng／mL。结论此方法可满足苯丙胺类毒品滥用者的血液定性定量分析。     

生物检材中吡氟氯禾灵（甲酯）的GC／MS检验

目的建立生物检材中吡氟氯禾灵（甲酯）的提取、检验方法。方法应用有机溶剂萃取，GC／MS检验。结果能有效提取、检验生物检材中吡氟氯禾灵（甲酯）。结论该提取、检验方法快速准确，结论可靠。     

固相萃取/气相色谱法检测全血中的扎来普隆

目的建立全血中扎来普隆的固相萃取/气相色谱检测方法。方法采用Oasis HLB固相萃取柱,5%甲醇水淋洗,二氯甲烷洗脱,GC/NPD定量检验,GC/MS定性检验,并对检测条件进行考察。结果扎来普隆与血中杂质分离良好,平均萃取回收率达89%以上,最低检出限20ng/mL,50～2000ng/mL内线性良好,相关系数R2=0.9945,日内RSD为3.1%～4.2%,日间RSD 5.8%～6.7%。结论该方法操作简便快速,提取回收率高,重现性好,提取物杂质少,可用于实际案件的检验。     

固相萃取技术分析生物检材中的鸦片成份

建立用国产GDX－403固相柱、GC／NPD毛细管气相色谱法，提取、净化生物检材中鸦片的方法。在1ml全血中添加1～4μg混合药物，回收率为79.2％～89.3％，RSD为2．61％～7．50％；在2g肝中添加2．5～10μg混合药物，回收率为72．9％～86．9％，RSD为2．27％～9．20％。该法回收率高，可用于检测人体内的微量鸦片成份。     

气相色谱-负化学源质谱法检测生物样品中佐匹克隆

目的建立气相色谱-负化学源质谱检验生物样品中佐匹克隆的方法。方法采用OasisHLB柱进行固相萃取,NCI-GC／MS检验。结果生物样品中佐匹克隆平均萃取回收率达75．8％,最低检出限0．01μg·mL^-1,线性良好,相关系数R^2=0．9989。结论该方法操作简便快速,提取回收率高,重现性好,提取物干净,可用于实际案件。     

人体血液中吗啡的定性定量分析

目的　建立人体血液中吗啡的定性定量分析方法。方法　经过丙酸酐衍生化法 ,利用气质联用和气相色谱氮磷检测器对吗啡丙酸酐衍生物进行定性定量分析。结果　确定了人体血液中吗啡的气质联用和气相色谱氮磷检测器定性定量分析的色谱条件、吗啡气相色谱氮磷检测器定量分析的线性范围及吗啡最小检出量0 1ng。结论　该方法定性定量结果准确、可靠 ,定量线性范围可满足实际办案需要 ,为吸食鸦片类毒品人群血液中吗啡的定性定量分析提供了分析方法和依据     

Evaluation of the Abbott TDx-radiative energy attenuation (REA) ethanol assay in a study of 1105 forensic whole blood specimens

In a preliminary study to determine the applicability of the Abbott radiative energy attenuation (REA) method for the quantification of ethanol in whole blood specimens it was concluded that a larger number of samples was required to evaluate the method, particularly for use in forensic toxicology applications. In this study, 573 blood specimens from suspected driving while intoxicated individuals (DWI blood) and 532 postmortem blood specimens (PM blood) were analyzed by the REA method and a headspace gas chromatographic method (GC) currently used in this laboratory. "Negative" specimens (less than 10 mg/dL by GC) and "positive" specimens (greater than or equal to 10 mg/dL by GC) in each category were analyzed. Linear regression analysis comparing the REA values with the GC values was performed for each type of blood specimen. The equation obtained for DWI blood specimens was REA = 0.943 GC + 1.54; the equation for PM blood specimens was REA = 0.980 GC + 2.76. The correlation coefficient for each group was greater than 0.99. The data suggested that a limit of detection of 10 mg/dL could be applied for DWI blood specimens, while 20 mg/dL would be recommended as the limit of detection for PM blood specimens.     

顶空GC／MS法检验血液中的硫化氢

目的建立血液中硫化氢的气相色谱质谱联用分析方法。方法取心血3mL-5mL,置于20mL顶空瓶中,加入1g氯化钠,加3mL-5mL蒸馏水,加入2mol／L盐酸1mL,加盖密封,混匀后于80℃水浴中加热20min。取液上气体0．5mL进样分析。结果在中毒死亡者的心血中检出硫化氢,保留时间参考值为3．6min。结论该方法可用于刑事案件中硫化氢的快速分析。     

HS-GC／FID分析血中的乙醚

目的建立顶空GC/FID分析血中乙醚的方法。方法用顶空GC/FID分析血中乙醚,并对萃取条件和色谱条件进行优化。结果方法的检出限为0.3ug/ml,回收率为81%,相对标准偏差为4.4%。结论该法简便、快速、灵敏,适合毒物分析检验的要求。     

Forensic toxicological analysis of tetrahydrofuran in body materials

Routine analysis of tetrahydrofuran (THF) in biologic materials has become feasible using GC and GC/MS and the headspace method. Problems of the headspace method and this substance which has a high water- and lipid-solubility were overcome by using the salting-out technique. Identification was made by mass spectral examination, in case of concentrations over 5 micrograms per sample. For quantitative determinations, tetrahydropyran (pentamethylene oxide) was used as an internal standard in GC, and a stable isotopic substance, octadeuterated THF (TDF) in GC/SIM. THF was detected in 1 microgram per sample by GC, and 0.1 microgram per sample by GC/SIM. THF blood levels in laboratory animals reached their highest values about 1 h after the oral administration, and the half-life was about 5 h. Ratios of tissue levels to blood were ca. 1.5-2 in the adipose tissue and kidney, and fairly equal in the brain, liver, spleen, and muscle.     

离子交换柱法萃取血样中4种巴比妥类药物

目的建立血样中4种常见巴比妥类药物的固相萃取方法。方法采用Oasis MAX固相萃取柱对样品进行预处理,以2%氨水淋洗2,%甲酸-甲醇洗脱,GC/NPD定量检验,GC/MS定性检验。结果血样中4种常见巴比妥类药物平均萃取回收率达80%以上,以信噪比10/1计,最小定量限为1～2μg/mL,以信噪比3/1计,检出限为0.5～1μg/mL,在1～50μg/mL范围内,线性相关系数均在0.99以上。结论本文固相萃取方法检出限低,回收率高,选择性强,可应用于血样中4种常见巴比妥类药物的检测。     

Zolpidem distribution in postmortem cases

Zolpidem is the prototype of a class of sedative hypnotic drugs that are derivatives of imidazopyridine and is sold in the United States under the trade name Ambien. Over a four-year period, zolpidem was identified in eight cases investigated by the Office of the Chief Medical Examiner, State of Maryland. Zolpidem was identified by gas chromatography-nitrogen-phosphorus detection (GC-NPD) following an alkaline extraction and was confirmed by full-scan electron impact gas chromatography/mass spectrometry. Zolpidem was quantitated by GC-NPD in all specimens received. Five of the cases presented were deaths due to drug intoxication. In three of these cases, zolpidem was an incidental finding because the drug fatalities resulted from other drugs. In the other two cases of drug intoxication, zolpidem was present in elevated concentrations and was a contributing, but not exclusive cause of the drug intoxication. The remaining three cases were deaths that were not caused by drugs. The blood zolpidem concentrations in these cases were therapeutic (0.28, 0.12 and 0.19 mg/L, respectively). In six of the eight cases where both blood and urine were analyzed, the blood concentration was higher than the urine concentration. The distribution of zolpidem into the liver and kidney failed to identify any sequestration of the drug into either specimen.     

中毒致死者体内芬氟拉明的GC/NPD,GC/MS法测定

建立了生物检材中芬氟拉明的定性定量分析方法。体液及脏器组织经有机溶剂提取后 ,用GC/MS法进行药物筛选、定性 ,生物检材中的芬氟拉明浓度用4 -苯丁胺作内标、GC/NPD法测定。测得芬氟拉明中毒致死者的血液、尿液、肝等组织中浓度分别为7.8μg/ml、64.2μg/ml、31.3μg/g。并对尸体解剖所见及方法可行性进行讨论     

Zolpidem and driving impairment

Zolpidem, a non-benzodiazepine hypnotic, was identified in the blood of 29 subjects arrested for impaired driving. Zolpidem concentrations ranged from 0.05 to 1.4 mg/L (mean 0.29 mg/L, median 0.19 mg/L). In the subjects whose cases we reviewed where zolpidem was present with other drugs and/or alcohol, symptoms reported were generally those of CNS depression. Symptoms included slow movements and reactions, slow and slurred speech, poor coordination, lack of balance, flaccid muscle tone, and horizontal and vertical gaze nystagmus. In five separate cases, where zolpidem was the only drug detected (0.08-1.40 mg/L, mean 0.65 mg/L, median 0.47 mg/L), signs of impairment included slow and slurred speech, slow reflexes, disorientation, lack of balance and coordination, and "blacking out." Although no quantitative relationship between blood concentrations and degree of driving impairment is currently possible, it is reasonable to conclude that because of its specific activity as a sleep inducer, blood concentrations consistent with therapeutic doses of zolpidem have the potential to affect driving in a negative way, and that concentrations above the normal therapeutic range would further impair a person's level of consciousness and driving ability.